Covid: WHO gives emergency approval to Cansino’s single-dose vaccine

The World Health Organization announced on Thursday the emergency approval of the Chinese company’s Convidicia vaccine against coronavirus CanSino Biologicswhile Beijing is fighting the resurgence of the pandemic.

This is the first anticovid serum approved by WHO this year, and thus joins a list that includes developments by Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca, Bharat Biotech, Novavax and the aforementioned Sinovac and Sinopharm.

The Chinese vaccine is based on a modified human adenovirus, which is administered a dose and recommended by the WHO for all age groups from the age of 18, according to the WHO statement.

This serum is achievable an effectiveness of 91.7% to prevent fatal cases of coronavirus, according to a phase 3 clinical study published Wednesday in The Lancet.

Doses of this vaccine have already been applied in Argentina. The government has even announced an agreement to buy millions of doses to then lose weight. Those who receive it in the country are from hard -to -reach populations, that is, people living on the streets or from marginal neighborhoods, migrants, and so on.

Earlier, the Nation announced a laboratory agreement for purchase and distribution of 5.4 million doses of Cansino. And there would have been many more if the Government had accepted requests from provinces such as Córdoba, Corrientes, Santa Fe, Buenos Aires and the City looking to them on opportunities to want to separate districts and close their own settlements.

Finally, Only 1,704,000 doses arrived in the country, according to the latest data provided by the Ministry of Health. And the rest of the deal remains to be seen, after Argentina decided not to order more batches of this Chinese drug.

Although this vaccine was initially thought of as an option to be a second dose of a Sputnik V, which was missing at the time, Health finally found another destination for it: it decided to target population far from urban centers, without the Internet, making it more difficult to access the vaccine.

By the end of 2021, a study published by The Lancet magazine revealed the effectiveness of a single-dose vaccine from Chinese laboratory CanSino Biologics Inc. was 91.7% in preventing severe coronavirus cases.

In that investigation it was also found that the only dose of the formula was 57.5% effective to prevent symptomatic covid-19.

After 28 days from vaccination, no serious adverse effects associated with the preparation were observed, nor were deaths recorded among trial participants, which included volunteers from five countries, including Argentina.

The vaccine can be stored for up to three months with refrigeration between 2 ° and 8 °, temperatures that reach standard refrigerators, which simplifies the process of its distribution.

A group of 36,727 people randomly received a vaccine developed by CanSinoBIO and the Beijing Institute of Biotechnology or a placebo injection, in 66 study centers in our country and in Chile, Mexico, Pakistan and Russia.

The analysis was conducted from samples collected up to January 15, 2021, so it does not evaluate the immune response to covid-19 variants that emerged later such as Delta and Omicron, The Lancet said in a statement.

DD